Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's Projections Have Not Changed Materially Con
(Financial Post, 2025-12-09T17:41:51Z)